Receive the Latest Events, News, Jobs, and Top Community Economic Development Stories Like this one Click Here | Reach up to 1.3 million people Promote
-------
Sickle Cell's Quiet Revolution: A Cure Exists - So Why Can't Black America Access It?
By AiSha | Digital Green Book for The Black News Scoop
Science has delivered something once considered impossible: a functional cure for sickle cell disease. Two gene therapies - Casgevy and Lyfgenia - earned FDA approval in December 2023, marking the first time gene editing has reached patients as an approved medical treatment. For the roughly 100,000 Americans living with sickle cell disease, about 90% of them Black, this should be front-page news every week. Mainstream media has largely moved on. The Black community deserves the full picture.
What These Treatments Actually Do
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR gene-editing technology to modify a patient's own stem cells, essentially reprogramming the blood to produce healthy hemoglobin. Lyfgenia, developed by bluebird bio, takes a similar approach through a different gene-delivery mechanism. Early clinical trial data shows both therapies eliminating the severe pain crises that define life with sickle cell disease for most patients. Researchers and physicians describe the outcomes as transformative, with many patients reaching pain-crisis-free status for multiple years post-treatment. blackenterprise.com
The Price Tag That Blocks the Door
Casgevy carries a list price of $2.2 million per treatment. Lyfgenia comes in at $3.1 million. These are one-time treatments, and manufacturers frame the cost against a lifetime of hospitalizations, transfusions, and lost productivity. For Black families navigating the real world, that framing provides little comfort.
Medicaid covers a significant share of sickle cell patients, since the disease disproportionately affects lower-income households. State Medicaid programs face enormous pressure absorbing costs at this scale, and coverage decisions vary widely by state. Many patients currently face a gap between the therapy existing and the therapy being accessible - a gap measured in millions of dollars. For Black households, where the median wealth sits at roughly $44,900, compared with $284,310 for white households according to Federal Reserve data, that gap functions as a wall. blavity.com
